Vincent Marks (10 June 1930 to 6 November 2023)

Diabetic MedicineVolume 41, Issue 3 e15274 INVITED REVIEW Vincent Marks (10 June 1930 to 6 November 2023) Peter R. Flatt, Peter R. Flatt School of Biomedical Sciences, Ulster University, Coleraine, UKSearch for more papers by this authorClifford J. Bailey, Corresponding Author Clifford J. Bailey [email protected] School of Life and Health Sciences, Aston University, Birmingham, UK Correspondence Clifford J. Bailey, School of Life and Health Sciences, Aston University, Gosta Green, Birmingham B4 7ET, UK. Email: [email protected]Search for more papers by this author Peter R. Flatt, Peter R. Flatt School of Biomedical Sciences, Ulster University, Coleraine, UKSearch for more papers by this authorClifford J. Bailey, Corresponding Author Clifford J. Bailey [email protected] School of Life and Health Sciences, Aston University, Birmingham, UK Correspondence Clifford J. Bailey, School of Life and Health Sciences, Aston University, Gosta Green, Birmingham B4 7ET, UK. Email: [email protected]Search for more papers by this author First published: 21 December 2023 https://doi.org/10.1111/dme.15274 An appreciation of his life and work. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat CONFLICT OF INTEREST STATEMENT The authors have no conflict of interest to declare. Open Research DATA AVAILABILITY STATEMENT Data sharing not applicable to this article as no datasets were generated or analysed during the current study. REFERENCES 1Marks V. An improved glucose-oxidase method for determining blood, C.S.F. and urine glucose levels. Clin Chim Acta. 1959; 4: 395-400. doi:10.1016/0009-8981(59)90110-x 10.1016/0009-8981(59)90110-X CASPubMedWeb of Science®Google Scholar 2Marks V. Rebirth of the incretin concept: its conception and early development. Peptides. 2018; 100: 3-8. doi:10.1016/j.peptides.2017.08.002 10.1016/j.peptides.2017.08.002 CASPubMedWeb of Science®Google Scholar 3Marks V, Rose EC, Samols E. Hyperinsulinism due to metastasizing insulinoma: treatment with diazoxide. Proc R Soc Med. 1965; 58: 577-578. CASPubMedWeb of Science®Google Scholar 4Marks V. Investigations of hypoglycaemia. In: D Pyke, ed. Disorders of Carbohydrate Metabolism. Pitman; 1964: 229-239. Google Scholar 5Samols E, Marri G, Marks V. Promotion of insulin secretion by glucagon. Lancet. 1965; 2(7409): 415-416. doi:10.1016/s0140-6736(65)90761-0 10.1016/S0140-6736(65)90761-0 CASPubMedWeb of Science®Google Scholar 6Samols E, Marri G, Marks V. Interrelationship of glucagon, insulin and glucose: the insulinogenic effect of glucagon. Diabetes. 1966; 15: 855-866. doi:10.2337/diab.15.12.855 10.2337/diab.15.12.855 CASPubMedWeb of Science®Google Scholar 7Lefebvre PJ, Unger E. Glucagon physiology. In: PJ Lefebvre, R Unger, eds. Glucagon, Molecular Physiology, Clinical and Therapeutic Implications. Pergamon Press; 1972: 213-224. Google Scholar 8Marks V, Samols E. Glucagon test for insulinoma: a chemical study in 25 cases. J Clin Pathol. 1968; 21: 346-352. doi:10.1136/jcp.21.3.346 10.1136/jcp.21.3.346 CASPubMedWeb of Science®Google Scholar 9Samols E, Stagner JI, Ewart RB, Marks V. The order of islet microvascular cellular perfusion is B-A-D in the perfused rat pancreas. J Clin Invest. 1988; 82: 350-353. doi:10.1172/JCI113593 10.1172/JCI113593 CASPubMedWeb of Science®Google Scholar 10Stagner JI, Samols E, Marks V. The anterograde and retrograde infusion of glucagon antibodies suggests that A cells are vascularly perfused before D cells within the rat islet. Diabetology. 1989; 32: 203-206. doi:10.1007/BF00265095 10.1007/BF00265095 CASPubMedWeb of Science®Google Scholar 11Conlon JM. The glucagon-like polypeptides - order out of chaos? Diabetologia. 1980; 18: 85-88. doi:10.1007/BF00290482 10.1007/BF00290482 CASPubMedWeb of Science®Google Scholar 12Samols E, Marks V. Nouvelles conceptions sur la signification fonctionnelle du glucagon (pancréatique et extrapancréatique) [New conceptions on the functional significance of glucagon (pancreatic and extra-pancreatic)]. Journ Annu Diabetol Hotel Dieu. 1967; 7: 43-66. CASPubMedGoogle Scholar 13Samols E, Tyler J, Marri G, Marks V. Stimulation of glucagon secretion by oral glucose. Lancet. 1965; 2(7425): 1257-1259. doi:10.1016/s0140-6736(65)92278-6 10.1016/S0140-6736(65)92278-6 CASPubMedWeb of Science®Google Scholar 14Samols E, Tyler J, Megyesi C, Marks V. Immunochemical glucagon in human pancreas, gut, and plasma. Lancet. 1966; 2(7466): 727-729. doi:10.1016/s0140-6736(66)92982-5 10.1016/S0140-6736(66)92982-5 CASPubMedWeb of Science®Google Scholar 15McIntyre N, Holdsworth CD, Turner DS. New interpretation of oral glucose tolerance. Lancet. 1964; 2(7349): 20-21. doi:10.1016/s0140-6736(64)90011-x 10.1016/S0140-6736(64)90011-X CASPubMedWeb of Science®Google Scholar 16Turner DS, Marks V. Enhancement of glucose-stimulated insulin release by an intestinal polypeptide in rats. Lancet. 1972; 1(7760): 1095-1097. doi:10.1016/s0140-6736(72)91431-6 10.1016/S0140-6736(72)91431-6 CASPubMedWeb of Science®Google Scholar 17Turner DS, Etheridge L, Marks V, Brown JC, Mutt V. Effectiveness of the intestinal polypeptides, IRP, GIP, VIP and motilin on insulin release in the rat. Diabetologia. 1974; 10: 459-463. doi:10.1007/BF01221638 10.1007/BF01221638 CASPubMedWeb of Science®Google Scholar 18Turner DS, Etheridge L, Jones J, et al. The effect of the intestinal polypeptides, IRP and GIP, on insulin release and glucose tolerance in the baboon. Clin Endocrinol (Oxf). 1974; 3: 489-493. doi:10.1111/j.1365-2265.1974.tb02820.x 10.1111/j.1365-2265.1974.tb02820.x CASPubMedWeb of Science®Google Scholar 19Marks V. The early history of GIP 1969-2000: from enterogastrone to major metabolic hormone. Peptides. 2020; 125: 170276. doi:10.1016/j.peptides.2020.170276 10.1016/j.peptides.2020.170276 CASPubMedWeb of Science®Google Scholar 20Brown JC. Gastric Inhibitory Polypeptide. Spinger Verlag; 1982. doi:10.1007/978-3-642-8771-7 10.1007/978-3-642-81771-7 Google Scholar 21Morgan LM, Morris BA, Marks V. Radioimmunoassay of gastric inhibitory polypeptide. Ann Clin Biochem. 1978; 15: 172-177. doi:10.1177/000456327801500138 10.1177/000456327801500138 CASPubMedWeb of Science®Google Scholar 22Marks V. The discovery of peptides used for the treatment of diabetes/obesity: a personal journey. Peptides. 2023; 170:171115. doi:10.1016/j.peptides.2023.171115 Published ahead of print. 10.1016/j.peptides.2023.171115 CASPubMedWeb of Science®Google Scholar 23Meier JJ, Nauck MA, Schmidt WE, Gallwitz B. Gastric inhibitory polypeptide: the neglected incretin revisited. Regul Pept. 2002; 107: 1-13. doi:10.1016/s0167-0115(02)00039-3 10.1016/S0167-0115(02)00039-3 CASPubMedWeb of Science®Google Scholar 24Elliott RM, Morgan LM, Tredger JA, Deacon S, Wright J, Marks V. Glucagon-like peptide-1 (7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns. J Endocrinol. 1993; 138: 159-166. doi:10.1677/joe.0.1380159 10.1677/joe.0.1380159 CASPubMedWeb of Science®Google Scholar 25Bailey CJ, Flatt PR, Conlon JM. An update on peptide-based therapies for type 2 diabetes and obesity. Peptides. 2023; 161:170939. doi:10.1016/j.peptides.2023.170939 10.1016/j.peptides.2023.170939 CASPubMedWeb of Science®Google Scholar 26Arendt J, Aldhous M, Marks V. Alleviation of jet lag by melatonin: preliminary results of controlled double blind trial. Br Med J (Clin Res ed). 1986; 292(6529): 1170. doi:10.1136/bmj.292.6529.1170 10.1136/bmj.292.6529.1170 CASPubMedGoogle Scholar 27Hampton SM, Morgan LM, Tredger JA, Cramb R, Marks V. Insulin and C-peptide levels after oral and intravenous glucose. Contribution of enteroinsular axis to insulin secretion. Diabetes. 1986; 35: 612-616. doi:10.2337/diab.35.5.612 10.2337/diab.35.5.612 CASPubMedWeb of Science®Google Scholar 28Marks V, Rose FC. Hypoglycaemia. 2nd ed. Blackwell Scientific Publications; 1981, [Translated into Spanish and Japanese]. Google Scholar 29Marks V, Richmond C. Insulin murders: true life cases. Royal Society of Medicine Press; 2007: 190. ISBN: 978-1-85315-760-8. Google Scholar 30O'Keefe SJ, Marks V. Lunchtime gin and tonic a cause of reactive hypoglycaemia. Lancet. 1977; 1(8025): 1286-1288. doi:10.1016/s0140-6736(77)91321-6 10.1016/S0140-6736(77)91321-6 PubMedWeb of Science®Google Scholar 31Marks V. Forensic Aspects of Hypoglycaemia. Taylor and Francis; 2019: 51 ISBN 10: 1138055697. Google Scholar 32Marks V, Cantor F, Pullman K, Mesko D. Differential Diagnosis by Laboratory Medicine. Springer; 2002. ISBN 10: 3540430571 [Translated into Chinese, Greek and republished in India, Greece and China]. 10.1007/978-3-642-55600-5 Google Scholar 33Feldman S, Marks V. Public Nation: Exposing the Myths We're Told About Food and Health. John Blake Publishing; 2016. ISBN 13: 9781844541225. Google Scholar 34Marks V. Is British Food Bad for You? Institute of Economic Affairs; 1991: 36 ISBN-10: 0255362676. Google Scholar 35Feldman S, Marks V. Global Warming and Other Bollocks. John Blake Publishing; 2007: 368. ISBN-10: 1782199071. Google Scholar Volume41, Issue3March 2024e15274 ReferencesRelatedInformation